Effects of Remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Cui, Guangxia ^a   Leng, Huijie ^a   Wang, Ke ^b   Wang, Jianwei ^b   Zhu, Sainan ^a   Jia, Jing ^c   Chen, Xing ^a   Zhang, Weiguang ^b   Qin, Lihua ^b   Bai, Wenpei ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; ESTRADIOL VALERATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE ATROPHY; BONE CHARACTERISTICS AND FUNCTIONS; BONE DENSITY; BONE INTEGRITY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR; LUMBAR VERTEBRA; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; TRABECULAR BONE; TREATMENT DURATION;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CIMICIFUGA; DISEASE MODELS, ANIMAL; FEMALE; OSTEOPOROSIS; OVARIECTOMY; PLANT EXTRACTS; RATS; TIME FACTORS;

EID: 84891918848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082815     Document Type: Article

References (46)

1. Ma B, Zhang Q, Wu D, Wang YL, Hu YY et al. (2012) Strontium fructose 1, 6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin 33:479-489. doi:10.1038/aps.2011.177. PubMed: 22426695.
2. Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:423-424. PubMed: 1421796.
3. Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF et al. (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18:69-76. PubMed: 17028792. (Pubitemid 44885497)
4. Choi SY, Park D, Yang G, Lee SH, Bae DK et al. (2011) Effects of Sigma Anti-bonding Molecule Calcium Carbonate on bone turnover and calcium balance in ovariectomized rats 27. Lab Anim Res. pp. 301-307.
5. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342. doi:10.1038/nature01658. PubMed: 12748652. (Pubitemid 40852708)
6. Petrovic O (1993) Estrogen and postmenopausal osteoporosis. Ann Intern Med 118:155-156. doi: 10.7326/0003-4819-118-2-199301150-00019. PubMed: 841631584163148416313.
7. Li X, Ominsky MS, Warmington KS, Morony S, Gong J et al. (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588. doi:10.1359/jbmr.081206. PubMed: 19049336.
8. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, et al. (1995) Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122:9-16
9. Cetinkaya MB, Kokcu A, Yanik FF, Başoǧlu T, Malatyalioglu E et al. (2002) Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women. J Bone Miner Metab 20:44-48. doi: 10.1007/s774-002-8446-8. PubMed: 11810416. (Pubitemid 34101095)
10. Petitti DB (2002) Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA 288:99-101. doi:10.1001/jama. 288.1.99. PubMed: 12090868. (Pubitemid 34705523)
11. Tang DZ, Hou W, Zhou Q, Zhang M, Holz J et al. (2010) Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res 25:1234-1245. doi: 10.1002/jbmr.21. PubMed: 20200936.
12. Colditz GA (1997) Hormone replacement therapy increases the risk of breast cancer. Ann N Y Acad Sci 833:129-136. doi:10.1111/j. 1749-6632.1997. tb48598.x. PubMed: 9616745. (Pubitemid 28045245)
13. Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G et al. (2010) Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 92:489-494. doi:10.1308/003588410X12699663903395. PubMed: 20522306.
14. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491. doi:10.1359/jbmr.0707onj. PubMed: 17663640. (Pubitemid 351229318)
15. Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L (2011) Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. Drug Des Devel Ther 5:445-454. PubMed: 22087064.
16. Hadji P (2012) The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric 15:513-523. doi: 10.3109/13697137.2012. 688079. PubMed: 22853318.
17. Nadaoka I, Watanabe K, Yasue M, Sami M, Kitagawa Y et al. (2012) Oral administration of Cimicifuga racemosa extract attenuates immobilization stress-induced reactions. Nat Prod Commun 7:15-18. PubMed: 22428232.
18. Liske E (1998) Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Ther 15:45-53. PubMed: 10178637. (Pubitemid 28125336)
19. Wade C, Kronenberg F, Kelly A, Murphy PA (1999) Hormonemodulating herbs: implications for women's health. J Am Med Womens Assoc 54:181-183
20. Nadaoka I, Yasue M, Sami M, Kitagawa Y (2012) Oral administration of Cimicifuga racemosa extract affects immobilization stress-induced changes in murine cerebral monoamine metabolism. Biomed Res 33:133-137. doi:10.2220/biomedres.33.133. PubMed: 22572387.
21. Beer AM, Osmers R, Schnitker J, Bai W, Mueck AO et al. (2013) Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms - comments on major statements of the Cochrane Collaboration report 2012 "black cohosh (Cimicifuga spp.) for menopausal symptoms (review) ". Gynecol Endocrinol (in press).
22. Ross SM (2012) Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 26:58-61. doi:10.1097/HNP. 0b013e31823d1f67. PubMed: 22157510.
23. Bai W, Henneicke-Von Zepelin HH, Wang S, Zheng S, Liu J et al. (2007) Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 58:31-41. doi:10.1016/j.maturitas.2007.04.009. PubMed: 17587516. (Pubitemid 47268705)
24. Firenzuoli F, Gori L, Di Sarsina Roberti (2011) P (2011) Black Cohosh Hepatic Safety: Follow-Up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature. Evid Based Complement Alternat Med, 2011:821392. PubMed: 21660145
25. Low Dog T, Powell KL, Weisman SM (2003) Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause 10:299-313. doi:10.1097/01. GME.0000056039.51813.21. PubMed: 12851513. (Pubitemid 36870502)
26. Naser B, Schnitker J, Minkin MJ, De Arriba SG, Nolte KU et al. (2011) Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause 18:366-375. doi:10.1097/gme.0b013e3181fcb2a6. PubMed: 21228727.
27. Nisslein T, Freudenstein J (2003) Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis. J Bone Miner Metab 21:370-376. doi:10.1007/s00774-003-0431-9. PubMed: 14586793. (Pubitemid 38017693)
28. Ma X, Zhang H, Wang K, Yang L, Qin L (2011) Effects of an isopropanolic-aqueous black cohosh extract on central body temperature of ovariectomized rats. J Ethnopharmacol 138:156-161. doi:10.1016/j.jep. 2011.08.076. PubMed: 21924343.
29. Racho. D, Vortherms T, Seidlova-Wuttke D, Wuttke W (2008) Effects of black cohosh extract on body weight gain, intra-abdominal fat accumulation, plasma lipids and glucose tolerance in ovariectomized Sprague-Dawley rats. Maturitas 60:209-215. doi:10.1016/j.maturitas. 2008.06.001. PubMed: 18691839.
30. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647-2656. doi:10.1002/jbmr.182. PubMed: 20641040.
31. Brzoska MM, Majewska K, Moniuszko-Jakoniuk J (2005) Weakness in the mechanical properties of the femur of growing female rats exposed to cadmium. Arch Toxicol 79:277-288. doi:10.1007/s00204-005-0650-z. PubMed: 15902425. (Pubitemid 40768450)
32. Yamazaki I, Yamaguchi H (1989) Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res 4:13-22. PubMed: 2718775. (Pubitemid 19079119)
33. Jakubowitz E, Seeger JB, Kretzer JP, Heisel C, Kleinhans JA et al. (2009) The influence of age, bone quality and body mass index on periprosthetic femoral fractures: a biomechanical laboratory study. Med Sci Monit 15:307-312. PubMed: 19865047.
34. Wronski TJ, Dann LM, Scott KS, Cintron M (1989) Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int, 45:45360-45366. PubMed: 2509027.
35. Ulrich D, Van Rietbergen B, Laib A, Ruegsegger P (1999) The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 25:55-60. doi:10.1016/S8756-3282 (99) 00134-9. PubMed: 10423022. (Pubitemid 29322061)
36. Devareddy L, Khalil DA, Smith BJ, Lucas EA, Soung Do Y et al. (2006) Soy moderately improves microstructural properties without affecting bone mass in an ovariectomized rat model of osteoporosis. Bone 38:686-693. doi:10.1016/j.bone. 2005.10.024. PubMed: 16406762.
37. Liu ZG, Zhang R, Li C, Ma X, Liu L et al. (2009) The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. J Ethnopharmacol 123:74-81. doi:10.1016/j.jep. 2009.02.025. PubMed: 19429343.
38. Laib A, Kumer JL, Majumdar S, Lane NE (2001) The temporal changes of trabecular architecture in ovariectomized rats assessed by MicroCT. Osteoporos Int 12:936-941. doi:10.1007/s001980170022. PubMed: 11804020. (Pubitemid 34001007)
39. Zhao X, Wu ZX, Zhang Y, Yan YB, He Q et al. (2011) Anti-osteoporosis activity of Cibotium barometz extract on ovariectomy-induced bone loss in rats. J Ethnopharmacol 137:1083-1088. doi:10.1016/j.jep. 2011.07.017. PubMed: 21782010.
40. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608. doi:10.1016/8756-3282 (93) 90081-K. PubMed: 8274302. (Pubitemid 23198821)
41. Sharir A, Barak MM, Shahar R (2008) Whole bone mechanics and mechanical testing. Vet J 177:8-17. doi:10.1016/j.tvjl.2007.09.012. PubMed: 17986396. (Pubitemid 351753678)
42. Einhorn TA (1992) Bone strength. Bottom Line - Calcif Tissue Int 51:333-339. doi:10.1007/BF00316875. (Pubitemid 23019410)
43. Bhattacharyya S, Siegel ER, Achenbach SJ, Khosla S, Suva LJ (2008) Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res 23:1106-1117. doi: 10.1359/jbmr.080235. PubMed: 18302502. (Pubitemid 351915733)
44. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T et al. (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812. doi:10.1359/JBMR.050403. PubMed: 16355501. (Pubitemid 41361881)
45. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318-3325. doi:10.1172/JCI27071. PubMed: 16322775. (Pubitemid 43121814)
46. Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D et al. (2005) Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J Bone Miner Res 20:2036-2043. doi:10.1359/JBMR.050716. PubMed: 16234977. (Pubitemid 41532789)